Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Development of a Prognostic and Predictive Biomarker for Locally Advanced Breast Cancer Patients Treated With Neoadjuvant Chemotherapy Using Exosome

NCT05955521 is registered in ClinicalTrials.gov with Samsung Medical Center as lead sponsor.

NCT NCT05955521
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05955521 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Development of a Prognostic and Predictive Biomarker for Locally Advanced Breast Cancer Patients Treated With Neoadjuvant Chemotherapy Using Exosome
Lead sponsor
Samsung Medical Center
Phase
Not applicable
Overall status
Active, not recruiting
Start date
May 1, 2021
Completion date
July 1, 2028
Enrollment
200 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

her2-positive breast cancer, triple negative breast cancer